CRO NACE Rev. 2 82.99 in IE. Official registry identity and a deliberately broad public benchmark curve on one indexed company profile.
A deliberately broad indicative range built from comparable companies with stronger filed or size evidence. It is not a company-specific appraisal, market value, asking price, or offer.
Broad benchmark based on comparable companies in this sector — not a company-specific appraisalOne public valuation range is currently available. A future eligible filing can extend this into a trend.
The historical curve shows where this company stood. Unlock what holds back value today, what it could be in five years and which actions matter now.
Free account · private workspace
Public filings are a starting point. Accounts, owner context and method review narrow the range and make it useful for a sale, financing or transfer.
Own this company? Claim and manage the profileThis broad public curve is a starting point based on governed sector or size evidence. Create a free account to refine it with verified company data and see the five-year outlook with concrete action points.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY, a CRO NACE Rev. 2 82.99, is registered at an address in Ireland. The company was founded in 2017, incorporated as a DAC - Designated Activity Company (limited by shares).
WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY is listed in Irish Companies Registration Office (CRO) under registry number 613112.
Within the Irish NACE 82.99 cluster, public-record data is filed annually via the national company registry.
WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY's public curve tracks a deliberately broad p10-p90 sector benchmark based on at least 30 comparable companies with stronger filed or size evidence. Its centre line is only the arithmetic middle of the published band: not a company-specific appraisal, sale price, offer, or recommendation.
The most recent annual filing covers 2024 (period end 2024-12-31).
It is a sector-level research range, not a company-specific appraisal, market value, asking price, offer, or investment recommendation.
WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY was founded in 2017 and is registered with Irish Companies Registration Office (CRO), incorporated as a DAC - Designated Activity Company (limited by shares).
WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY is registered under NACE 82.99: CRO NACE Rev. 2 82.99. That places the business within the Irish cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via Irish Companies Registration Office (CRO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for WO-SUMICAV 110 DESIGNATED ACTIVITY COMPANY may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
